Triptans do not Increase Risk of Stroke in Migraine
نویسندگان
چکیده
منابع مشابه
Triptans for migraine prodrome.
CLINICAL HISTORY A 43-year-old woman has a history of recurrent migrainous headaches since aged 7 years. She develops blurred vision, goose bumps on her arms, slight nausea, clear nasal drainage, and a “tight” feeling in the right superior trapezius area, followed the next day by severe, incapacitating, right-sided headache with associated nausea and light sensitivity, lasting 3 days. These epi...
متن کاملTriptans for the management of migraine.
Migraine is a chronic, recurrent, disabling condition that affects millions of people in the US and worldwide. Proper acute care treatment for migraineurs is essential for a full return of function and productivity. Triptans are serotonin (5-HT)(1B/1D) receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available worldwide, although not all are available ...
متن کاملTriptans for symptomatic treatment of migraine headache.
Department of Clinical Neurosciences, Psychiatry, Pediatrics, and Community Health Sciences, University of Calgary, Calgary, Alberta Children’s Hospital, Calgary, AB, Canada T3B 6A8 Department of Clinical Neurosciences, University of Calgary, Calgary, Foothills Medical Centre, Calgary, AB, Canada Correspondence to: T Pringsheim [email protected] Cite this as: BMJ 2014;348:g2285 doi: 10.1136/...
متن کاملStroke Migraine Mutations Increase Stroke Vulnerability by Facilitating Ischemic Depolarizations
Background—Migraine is an independent risk factor for stroke. Mechanisms underlying this association are unclear. Familial hemiplegic migraine (FHM), a migraine subtype that also carries an increased stroke risk, is a useful model for common migraine phenotypes because of shared aura and headache features, trigger factors, and underlying glutamatergic mechanisms. Methods and Results—Here, we sh...
متن کاملAngiotensin receptor blockers do not increase risk of myocardial infarction.
The efficacy and safety of angiotensin-converting enzyme (ACE) inhibitors has been well established; these agents have shown an overwhelming and unequivocal benefit in placebo-controlled trials across a spectrum of patients at risk for cardiovascular events.1–9 What has been less clear, however, is whether inhibition of the renin-angiotensin-aldosterone system with angiotensin receptor blockers...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Neurology Briefs
سال: 2004
ISSN: 2166-6482,1043-3155
DOI: 10.15844/pedneurbriefs-18-3-2